Show simple item record

dc.contributor.author许佳音
dc.contributor.author郑建洪
dc.date.accessioned2018-11-26T08:57:17Z
dc.date.available2018-11-26T08:57:17Z
dc.date.issued2016-04-19
dc.identifier.citation中国新药杂志,2016,25(07):12-14
dc.identifier.issn1003-3734
dc.identifier.otherZXYZ201607003
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/165786
dc.description.abstract乐伐替尼是一种口服多靶点酪氨酸激酶抑制剂,2015年2月13日获得美国食品药品监督管理局(FDA)批准,用于治疗局部复发或转移病灶进展性放射性碘(131I)难治性分化型甲状腺癌(RR-DTC)。本文对乐伐替尼的药理作用、药动学、临床评价、安全性以及药物相互作用等进行了综述。
dc.description.abstractLenvatinib is an oral,multitargeted tyrosine kinase inhibitor. It was approved for the treatment of locally recurrent or metastatic,progressive,radioactive iodine-refractory differentiated thyroid cancer by FDA in February 13,2015. The pharmacology,pharmacokinetics,clinical evaluation,safety,and drug interactions of lenvatinib were reviewed in this paper.
dc.language.isozh_CN
dc.subject乐伐替尼
dc.subject酪氨酸激酶抑制剂
dc.subject分化型甲状腺癌
dc.subject药理作用
dc.subject临床评价
dc.subjectlenvatinib
dc.subjecttyrosine kinase inhibitor
dc.subjectdifferentiated thyroid cancer
dc.subjectpharmacology
dc.subjectclinical evaluation
dc.title乐伐替尼的药理和临床评价
dc.title.alternativePharmacological and clinical evaluation of lenvatinib
dc.typeArticle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record